谭东涵 / Tan Donghan

Overview

谭东涵 is the medically trained investment guest in a 这病说来话长 discussion of Chinese innovative drugs, ASCO visibility, payment, licensing, and globalization.

Current Profile

The source says 谭东涵 moved from clinical medicine into finance and investment because he wanted a form of leverage capable of affecting more patients than one-at-a-time clinical care. In the episode, he interprets Chinese innovative drugs as an industry system: unmet need, research, trials, capital, regulation, reimbursement, licensing, and global commercialization have to work together.

His assessment is optimistic but conditional. China has a large market, unified regulation and insurance structures, extensive clinical resources, rapid organizational execution, and increasingly competitive assets, yet weaker payment capacity and incomplete original-science and global-commercial capabilities still limit leadership. He treats cross-border partnership as a normal part of biotech rather than automatic surrender, while allowing that only a small number of Chinese firms may build full multinational-pharma capabilities.

Key Characteristics

• Combines medical training with an investment and industry-structure perspective.
• Frames innovative drugs around unmet clinical need, high risk, long timelines, and value capture.
• Treats payment capacity as part of the innovation system rather than a downstream detail.
• Distinguishes ordinary biotech licensing from the rarer task of building a multinational pharmaceutical company.
• Sees Chinese execution capacity as real while keeping original discovery and globalization gaps explicit.

Evidence

• Career and leverage: VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 says he moved from clinical medicine into investing to seek broader impact.
• Industry transition: VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 has him distinguish innovation-drug economics from generic manufacturing and place China’s industry in a movement from following toward innovation.
• Payment and access: VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 has him connect low domestic innovative-drug sales and payer mix with the need for layered insurance and overseas markets.
• Partnership and globalization: VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 has him defend licensing as a normal biotech outcome while arguing that China may still produce a few firms with multinational capabilities.
• Originality boundary: VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 has him distinguish rapid work in known modalities from the basic science and translation needed when the next direction is unknown.

Qualifications

The wiki has only this podcast note for 谭东涵 and no independent biography, employment history, credential verification, or investment record. Numerical market, pricing, payer, conference, development-cost, and longevity claims attributed to him remain source-scoped and are not investment or medical advice.

What Changed

• Established a source-bounded profile connecting medical training, investment, payment, licensing, and original innovation.

Relationships

• 大白牛老师 / Daba Niu Teacher - fellow guest contributing clinical and drug-development interpretation.
• 小龙 / Xiaolong (Weight-Management Guest) - fellow guest contributing public-health and clinical-development execution context.
• China Research Visibility at ASCO - international-visibility trend he interprets as meaningful but incomplete progress.
• Innovative Drug Payment Sustainability - access and innovation tradeoff central to his argument.
• China Biotech Globalization - global value-capture path he treats as strategically necessary for some firms.
• China Innovative Drug Execution–Originality Gap - boundary between speed in known directions and leadership in uncertain ones.